Pancreatic Cancer
CSHL has several researchers working on pancreatic cancer. David Tuveson, M.D., Ph.D., Professor, directs the Lustgarten Foundation Pancreatic Cancer Research Laboratory at CSHL.
Help fund this research
* NOTE: On the donation form indicate in the comments field that you want your donation to go towards pancreatic cancer research.
Lustgarten Foundation Pancreatic Cancer Research Laboratory
The Lustgarten Foundation Pancreatic Cancer Research Laboratory at CSHL, led by聽David Tuveson, M.D., Ph.D. is centered on early detection, drug development and drug delivery. The research will focus initially on three key aspects of pancreatic cancer:
- Developing ways to detect pancreatic cancer early—The presence of cancer in the pancreas聽causes changes in a person鈥檚 system that may be detected in bodily fluids, such as blood or urine.聽 These changes will be identified so that they can be used to routinely test patients for the presence of pancreatic cancer in its earliest stages.
- Identifying new targets for drug development—New pathways will be explored that could potentially uncover new therapeutic approaches for drug development to kill and eliminate pancreatic cancers.
- Using more effective approaches to deliver drugs directly to pancreatic cancers—Existing research shows that pancreatic tumors are difficult to penetrate with chemotherapy, so new methods will be developed to ensure that the chemotherapy reaches the tumor for more effective treatment.
In addition to directing the Lustgarten Foundation Pancreatic Cancer Research Laboratory at CSHL, Dr. Tuveson is also the Director of Research for the . In this capacity, he oversees the development of fundable research and works with the Foundation鈥檚 Pancreatic Cancer Research Consortium of six, world-renowned medical institutions to identify, prioritize and develop targeted research aimed at ultimately finding a cure for this deadly disease.
- , Ph.D.
- Douglas Fearon, Ph.D.
- David Tuveson, M.D., Ph.D.
Let鈥檚 get on pancreatic cancer鈥檚 nerves
February 9, 2026
CSHL postdoc Jeremy Nigri and colleagues in the Tuveson lab have discovered that the nervous system plays a role in pancreatic cancer development.
Short-circuiting pancreatic cancer
January 8, 2026
Applying CSHL researchers鈥 new RNA therapeutic is 鈥渓ike killing three birds with one stone.鈥
Shapeshifting cancers鈥 masters, unmasked
November 24, 2025
New research from CSHL鈥檚 Vakoc lab helps explain the bizarre behavior of certain pancreatic cancers and lung cancers that can change identities.
NCI grants support 鈥榥atural鈥 cancer research
August 11, 2025
CSHL鈥檚 Moses lab uses a technique called click chemistry to create new, nature-based compounds that could one day be used in the clinic.
At the Lab: Catch me if you cancer
June 3, 2025
You鈥檝e seen her on FOX and the cover of Newsday. Now, hear about the knowledge gaps that make her discovery so crucial and the noble goals driving it.
In pancreatic cancer, a race against time
April 2, 2025
By the time it鈥檚 diagnosed, it鈥檚 often too late. Now, 黑料吃瓜资源 researchers have found a way to intercept the deadly disease.
Cocktails & Chromosomes: Cancer鈥檚 identity crisis
December 19, 2024
CSHL Professor Christopher Vakoc shares his research with a standing-room-only crowd at Industry bar in Huntington, NY.
Flipping cancer鈥檚 off switch
November 7, 2024
CSHL Professor Christopher Vakoc and postdoc Olaf Klingbeil have found a potential drug target for some of the most common and deadly cancers.
At the Lab Season 1 Research Rewind: Cancer
October 8, 2024
As the first season of our new podcast winds down, we鈥檙e revisiting all of our episodes with a focus on CSHL鈥檚 cutting-edge cancer research.
Old chemo drug, new pancreatic cancer therapy?
August 26, 2024
CSHL scientists have found that folinic acid makes immunotherapy therapy more effective against pancreatic ductal adenocarcinoma in mice.









